Russia’s Sechenov University successfully completes clinical trials of Coronavirus vaccine
Clinical trials of the world’s very first vaccine for Coronavirus have been concluded by Russia’s Sechenov First Moscow State Medical University.
The clinical trials of the first vaccine for the Coronavirus throughout the world have been concluded by Russia’s Sechenov First Moscow State Medical University. Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, confirmed this piece of information stated a report by Sputnik News.
The report even emphasized that all the clinical trials of the COVID-19 vaccine developed by the Gamalei Institute of Epidemiology and Microbiology had began on June 18.
The report stated that both the groups of volunteers who were considered for conducting the clinical trials will be discharged soon. The first group will be allowed to depart in two-three days whereas the second group will be allowed to depart on July 20.
Referring to the director of the Institute of Medical Parasitology, Tropical, and Vector-Borne Diseases at Sechenov University, Alexander Lukashev, the report indicated that the research has been conducted to review vaccine’s safety when given to humans and that has now been successfully concluded.
Lukashev informed that now the safety has been approved, it even implies that the vaccines that are already in the market are secure too.
Additionally, the vaccine manufacturer is making a plan for the development of this vaccine that will incorporate the “complexity of the epidemiological situation with the virus” and how to accelerate the vaccine’s production, the report stated.
Tarasov indicated that Sechenov University has grown as a scientific and technological research center for this vaccination than just being an educational establishment at a crucial time when countries are struggling under the pressure of rapid Coronavirus transmission. He even told that the Institute for Translational Medicine and Biotechnology has operated with preclinical studies, protocol development along with clinical trials of this vaccine.
At the same time, in the previous month, the World Health Organisation had declared that Oxford’s vaccine was most progressive amongst them all. It is anticipated to be available in the market as soon as possible as AstraZeneca by Oxford is in the third stage of its clinical trials.